Advanced search
Publication Cover
Drug Delivery Volume 25, 2018 - Issue 1
Submit an article Journal homepage
901
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Modified translationally controlled tumor protein-derived protein transduction domain enhances nasal delivery of exendin-4 as shown with insulin

Hae-Duck BaeGraduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul, South KoreaView further author information
,
Moonhee KimGraduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul, South KoreaView further author information
,
Joohyun LeeGraduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul, South KoreaView further author information
&
Kyunglim LeeGraduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul, South KoreaCorrespondence[email protected]
View further author information
Pages 1579-1584 | Received 15 May 2018, Accepted 18 Jun 2018, Published online: 25 Jul 2018

References

  • Bae HD, Lee J, Jun KY, et al. (2018). Modification of translationally controlled tumor protein-derived protein transduction domain for improved intranasal delivery of insulin. Drug Deliv 25:1025–32.
  • Bae HD, Lee K. (2013). On employing a translationally controlled tumor protein-derived protein transduction domain analog for transmucosal delivery of drugs. J Control Release 170:358–64.
  • Battaglia L, Panciani PP, Muntoni E, et al. (2018). Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery. Expert Opin Drug Deliv 15:369–78.
  • Bolhassani A, Jafarzade BS, Mardani G. (2017). In vitro and in vivo delivery of therapeutic proteins using cell penetrating peptides. Peptides 87:50–63.
  • Chien YW, Chang SF. (1987). Intranasal drug delivery for systemic medications. Crit Rev Ther Drug Carrier Syst 4:67–194.
  • Davis SS, Illum L. (2003). Absorption enhancers for nasal drug delivery. Clin Pharmacokinet 42:1107–28.
  • Gros E, Deshayes S, Morris MC, et al. (2006). A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction. Biochim Biophys Acta 1758:384–93.
  • Jiang Y, Li M, Zhang Z, et al. (2014). Cell-penetrating peptides as delivery enhancers for vaccine. Curr Pharm Biotechnol 15:256–66.
  • Khafagy El S, Morishita M, Takayama K. (2010). The role of intermolecular interactions with penetratin and its analogue on the enhancement of absorption of nasal therapeutic peptides. Int J Pharm 388:209–12.
  • Kim M, Kim M, Kim HY, et al. (2011a). A protein transduction domain located at the NH2-terminus of human translationally controlled tumor protein for delivery of active molecules to cells. Biomaterials 32:222–30.
  • Kim M, Maeng J, Jung J, et al. (2011b). Design and evaluation of variants of the protein transduction domain originated from translationally controlled tumor protein. Eur J Pharm Sci 43:25–31.
  • Kristensen M, De Groot AM, Berthelsen J, et al. (2015). Conjugation of cell-penetrating peptides to parathyroid hormone affects its structure, potency, and transepithelial permeation. Bioconjugate Chem 26:477–88.
  • Maiolo JR, Ferrer M, Ottinger EA. (2005). Effects of cargo molecules on the cellular uptake of arginine-rich cell-penetrating peptides. Biochim Biophys Acta 1712:161–72.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.